4-氰基吡啶-3-硼酸频哪醇酯 | 878194-91-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氰基吡啶-3-硼酸频哪醇酯
• 中文别名: 4-氰基吡啶-3-硼酸频那醇酯；4-氰基吡啶-5-硼酸频哪醇酯；4-氰基-3-(4,4,5,5-四甲基-[1,3,2]二氧硼戊环-2-基)吡啶
• 英文名称: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isonicotinonitrile
• 英文别名: 4-cyanopyridine-3-boronic acid pinacol ester；3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-4-carbonitrile
• CAS: 878194-91-3
• 化学式: C₁₂H₁₅BN₂O₂
• mdl: MFCD08458478
• 分子量: 230.074
• InChiKey: DQQFRFWEPQBNEN-UHFFFAOYSA-N

物化性质

• 熔点：
  84-88℃
• 沸点：
  365.5±27.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  按规定使用和贮存的不会分解，避光以防止氧化。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319
• 储存条件：
  请将药品存放在密闭、阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Cyanopyridine-3-boronic acid pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Cyanopyridine-3-boronic acid pinacol ester
CAS number: 878194-91-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H15BN2O2
Molecular weight: 230.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氰基吡啶-3-硼酸频哪醇酯 在 copper(l) iodide 、 四(三苯基膦)钯 氢氧化钾 、 cesium fluoride 、 三氯氧磷 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.67h， 生成 6-氯吡啶并[4,3-c][1,5]萘啶
  参考文献：
  名称：

  合成三个新的杂环：吡啶并[4,3或3,4或2,3- c ] -1,5-萘啶

  摘要：

  从母体吡啶并吡啶并吡啶酮开始进行氯脱羟基化和脱卤反应后，可得到高产率的吡啶并[4,3或3,4或2,3 - c ] -1,5-萘啶。使用2-氯-3-氟吡啶与原氰基吡啶基硼酸酯之间的Suzuki交叉偶联反应，然后进行KOH介导的阴离子闭环，以两步法合成这些吡啶并萘并吡啶并酮。

  DOI：

  10.1016/j.tet.2006.10.046
• 作为产物：
  描述：

  C₁₂H₁₇BN₂O₂ 在 盐酸 、 magnesium sulfate 作用下， 以 甲苯 为溶剂， 反应 12.0h， 生成 4-氰基吡啶-3-硼酸频哪醇酯
  参考文献：
  名称：

  Synthesis ofortho-Cyanopyridylboronic Acids and Esters toward Cyano-Functionalized Bipyridines

  摘要：

  这项工作描述了邻氰基吡啶硼酸和酯的合成。评估了它们与吡啶卤化物在铃木交叉偶联反应中的反应性，结果表明氰基吡啶硼酸酯似乎比其对应的酸更稳定。这些酯使我们能够合成新的氰基双吡啶体系。

  DOI：

  10.1055/s-2005-922772

文献信息

• NAPHTHYRIDINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282328A1

  公开（公告）日：2018-10-04

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  萘啶化合物及其作为HPK1抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面很有用。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES POUR LE TRAITEMENT DE MALADIES
  申请人：GALAPAGOS NV

  公开号：WO2019105886A1

  公开（公告）日：2019-06-06

  The present invention discloses compounds according to Formula (I): wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNFα, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

  本发明公开了根据式(I)的化合物：其中R1、R2、R3a、R3b、X、Y1、Y2、Y3和Z如本文所定义。本发明涉及化合物、其生产方法、包括其在内的药物组合物，以及使用这些化合物进行预防和/或治疗炎症性疾病、自身炎症性疾病、自身免疫性疾病、增殖性疾病、纤维化疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形、涉及骨周转障碍的疾病、与TNFα、干扰素、IL-6、IL-12和/或IL-23过度分泌相关的疾病、呼吸系统疾病、内分泌和/或代谢性疾病、心血管疾病、皮肤病和/或异常血管生成相关疾病的预防和/或治疗方法，通过给予本发明的化合物。
• [EN] BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1<br/>[FR] DÉRIVÉS DE BENZAMIDE POUR INHIBER L'ACTIVITÉ D'ABL1, D'ABL2 ET DE BCR-ABL2
  申请人：NOVARTIS AG

  公开号：WO2013171640A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式(I)的化合物：其中Y、Y、R、R 2、R 3和R 4在发明摘要中有定义；能够抑制BCR-ABL1及其突变体的活性。本发明还提供了一种制备本发明化合物的方法，包括含有这种化合物的药物制剂以及使用这种化合物治疗癌症的方法。
• The direct arylation of allylic sp3 C–H bonds via organic and photoredox catalysis
  作者：James D. Cuthbertson、David W. C. MacMillan

  DOI：10.1038/nature14255

  日期：2015.3.5

  particular, the direct arylation of non-functionalized allylic systems would enable access to a series of known pharmacophores (molecular features responsible for a drug’s action), though a general solution to this long-standing challenge remains elusive. Here we report the use of both photoredox and organic catalysis to accomplish a mild, broadly effective direct allylic C–H arylation. This C–C bond forming

  未活化的 sp3 C-H 键的直接功能化仍然是合成有机化学家面临的最具挑战性的问题之一。这种转变的吸引力来自于它们通过简单和其他惰性结构单元的耦合促进复杂有机分子构建的能力，而不会引入无关的官能团。尽管最近做出了显着的努力，但事实证明，为 sp3 C-H 键参与 C-C 键形成反应建立一般和温和的策略是困难的。在此背景下，发现能够以催化方式直接使烯丙基甲基、亚甲基和次甲基碳官能化的化学转化是当务之急。尽管烯丙基 C-H 键的直接氧化和胺化方案（即，C-H 键，其中相邻的碳参与 C = C 键）已经广泛建立，烯丙基底物在 C-C 键形成反应中的参与迄今为止需要使用预官能化的偶联伙伴。特别是，非功能化烯丙基系统的直接芳基化将能够获得一系列已知的药效团（负责药物作用的分子特征），尽管解决这一长期挑战的通用解决方案仍然难以捉摸。在这里，我们报告了使用光氧化还原和有机催化来完成温和、广泛有效的直接烯丙基
• [EN] CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER<br/>[FR] COMPOSÉS DE CINNOLINE POUR LE TRAITEMENT DE TROUBLES DÉPENDANT DU HPK1 TELS QUE LE CANCER
  申请人：GENENTECH INC

  公开号：WO2020069402A1

  公开（公告）日：2020-04-02

  Cinnoline compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.

  该文描述了化学式(I)的喹啉化合物及其变体，以及它们作为HPK1（造血激酶1）抑制剂的用途。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面具有用途。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备喹啉化合物的方法。